Stay updated with breaking news from Planegg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-Ad-hoc: MorphoSys AG / Key word: Change in Forecast Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for...
Drug discovery company Morphosys expects slightly more business this year for its key blood cancer drug Monjuvi in the United States. Given preliminary sales of the drug in the third quarter, the...
MorphoSys AG / Key word(s): Change in ForecastAd hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 202325-Oct-2023 / 10:48 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News...
EQS-News: MorphoSys AG / Key word(s): Change in ForecastMorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 25.10.2023 / 10:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Planegg/Munich, Germany, October 25, 2023 Mo...
![MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -October 25, 2023 at 10:01 am EDT - Vimarsana News](https://www.marketscreener.com/images/twitter_MS_fdnoir.png)
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...